Flag of the European Union EU Clinical Trials Register Help

Clinical trials for combination

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44332   clinical trials with a EudraCT protocol, of which   7365   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    821 result(s) found for: combination. Displaying page 1 of 42.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-003141-28 Sponsor Protocol Number: CCR4500 Start Date*: 2017-04-04
    Sponsor Name:The Institute of Cancer Research
    Full Title: ACE: Proof of concept Phase I/II trial of the CXCR2 antagonist AZD5069, administered in combination with enzalutamide, in patients with metastatic castration resistant prostate cancer(mCRPC)
    Medical condition: Metastatic castration resistant prostate cancer
    Disease:
    Population Age: Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-001216-19 Sponsor Protocol Number: Start Date*: 2014-11-13
    Sponsor Name:NHS Greater Glasgow & Clyde [...]
    1. NHS Greater Glasgow & Clyde
    2. University of Glasgow
    Full Title: Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose e...
    Medical condition: glioblastoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-003485-40 Sponsor Protocol Number: CCR5163 Start Date*: 2020-10-01
    Sponsor Name:The Institute of Cancer Research
    Full Title: ACTION: Phase I/II Trial of Abiraterone Acetate in Combination with Tildrakizumab (anti-IL23 targeting monoclonal antibody) in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Medical condition: Metastatic castration resistant prostate cancer
    Disease:
    Population Age: Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-003408-29 Sponsor Protocol Number: 5F9003 Start Date*: 2019-11-04
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
    Medical condition: Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012821 Diffuse large B-cell lymphoma recurrent PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029624 Non-Hodgkin's lymphoma unspecified histology indolent stage III PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029601 Non-Hodgkin's lymphoma refractory PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029600 Non-Hodgkin's lymphoma recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029623 Non-Hodgkin's lymphoma unspecified histology indolent stage II PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029622 Non-Hodgkin's lymphoma unspecified histology indolent stage I PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-013645-29 Sponsor Protocol Number: 120609 Start Date*: 2009-08-07
    Sponsor Name:Epsom & St Helier's University Hospital NHS Trust
    Full Title: A Two Phase Prospective Randomized Control Trial of Infiltrated Periarticular Multimodal Analgesia following Primary Total Hip Replacement
    Medical condition: Pain relief after total hip replacement
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-004231-23 Sponsor Protocol Number: 274948 Start Date*: 2020-05-29
    Sponsor Name:Queen Mary University of London
    Full Title: Phase IIb randomised clinical trial repurposing ATRA as a stromal targeting agent in a novel drug combination for pancreatic cancer
    Medical condition: Pancreatic cancer - locally advanced
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-001879-20 Sponsor Protocol Number: RG_13-107 Start Date*: 2013-12-30
    Sponsor Name:University of Birmingham
    Full Title: Phase I/II study to determine the maximum tolerated dose and activity of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma
    Medical condition: Peripheral T-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034626 Peripheral T-cell lymphoma unspecified refractory PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034625 Peripheral T-cell lymphoma unspecified recurrent PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-003857-73 Sponsor Protocol Number: D6130C00003 Start Date*: 2019-09-26
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refr...
    Medical condition: Treatment Naïve or Relapsed/Refractory Acute Myeloid Leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-004332-36 Sponsor Protocol Number: DTX-SPL8783-002 Start Date*: 2020-02-01
    Sponsor Name:Starpharma Pty Ltd
    Full Title: A Phase 1/2 Modular, Multi-Arm Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of DTX-SPL8783 (DEP docetaxel/DEP-DTX) in Combination with Anti-Cancer Treatments, in Patients wit...
    Medical condition: Advanced malignant solid tumours
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-001879-37 Sponsor Protocol Number: GB1275-1101(KEYNOTE-A36) Start Date*: 2020-01-14
    Sponsor Name:GB006, Inc., a wholly-owned subsidiary of Gossamer Bio, Inc.
    Full Title: A Phase 1/2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combination with an Anti-PD-1 Antibody in Patients with Specified Advanced Solid Tumors or in Combination...
    Medical condition: Phase 1: Advanced solid tumors, metastatic pancreatic adenocarcinoma Phase 2: Specified metastatic solid tumors
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2011-005023-40 Sponsor Protocol Number: RG_11-182 Start Date*: 2013-05-22
    Sponsor Name:University of Birmingham
    Full Title: ROMAZA: Phase I trial of combination therapy with romidepsin and azacitidine in patients with newly diagnosed, relapsed or refractory Acute Myeloid Leukaemia ineligible for conventional chemotherapy
    Medical condition: Acute myeloid leukaemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-003213-18 Sponsor Protocol Number: RHMCAN1129 Start Date*: 2017-01-13
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: A Phase Ib/II combination trial of acalabrutinib with rituximab, cyclophosphamide, doxorubicin,vincristine and prednisolone (R-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL)
    Medical condition: Diffuse large B-cell lymphomas (most common type of non-Hodgkins lymphoma)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-004091-34 Sponsor Protocol Number: CCR3972 Start Date*: 2014-03-26
    Sponsor Name:The Royal Marsden NHS Foundation Trust [...]
    1. The Royal Marsden NHS Foundation Trust
    2. The Institute of Cancer Reseacrh
    Full Title: A randomised Phase II study of Enzalutamide (MDV3100) in combination with AZD5363 in Patients with Metastatic Castration - Resistant Prostate Cancer
    Medical condition: Metastatic Castration- Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-004509-42 Sponsor Protocol Number: CTL-101-023 Start Date*: 2018-04-23
    Sponsor Name:Celleron Therapeutics Ltd
    Full Title: A Phase Ib/ II Trial to Assess the Safety and Efficacy of CXD101 in Combination with the PD-1 Inhibitor Nivolumab in Patients with Metastatic, Previously-Treated, Microsatellite-Stable Colorectal C...
    Medical condition: Metastatic, Previously-Treated, Microsatellite-Stable Colorectal Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010036 Colorectal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-005629-65 Sponsor Protocol Number: RG_12-269 Start Date*: 2014-01-15
    Sponsor Name:University of Birmingham
    Full Title: Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose finding study
    Medical condition: Chronic Myeloid Leukaemia (CML) in Blast Phase
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-001034-35 Sponsor Protocol Number: RG_19-138 Start Date*: 2020-10-15
    Sponsor Name:University of Birmingham
    Full Title: Accelerating the Development and implementation of Personalised Treatments of DNA Damage Response agents and radiotherapy +/- immunotherapy for head and neck squamous cell cancer
    Medical condition: Head and neck squamous cell carcinoma (HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-003928-31 Sponsor Protocol Number: GN15ON133 Start Date*: 2016-09-22
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University Of Glasgow
    Full Title: A Phase I/IIA Study to Assess Safety, Tolerability and Preliminary Activity of the Combination of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Patients with Advanced Solid Malignancies
    Medical condition: Advanced, incurable cancer with no remaining standard-of-care treatment options that are suitable. Or where pembrolizumab is a licensed treatment option at that line of therapy. In Phase I, this ma...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033633 Pancreatic neoplasms malignant (excl islet cell and carcinoid) HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029664 Non-small cell neoplasms malignant of the respiratory tract cell type specified HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027414 Mesotheliomas malignant and unspecified HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-001321-17 Sponsor Protocol Number: 11275 Start Date*: 2016-12-02
    Sponsor Name:University of Oxford
    Full Title: A randomised control trial of 5-Aminolevulinic Acid in combination with Sodium Ferrous Citrate to Enhance Cardioprotection in Adults undergoing Cardiac Surgery
    Medical condition: Low cardiac output states following cardioplegic arrest for cardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004863 10007602 Cardiac and vascular procedural complications HLT
    19.0 10007541 - Cardiac disorders 10051624 Myocardial reperfusion injury PT
    19.0 10042613 - Surgical and medical procedures 10066123 Cardiopulmonary bypass PT
    19.0 10007541 - Cardiac disorders 10024920 Low output state LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-004019-34 Sponsor Protocol Number: ABI-H0731-211 Start Date*: 2019-02-20
    Sponsor Name:Assembly Biosciences
    Full Title: A Multi-center, Open-label, Long-term Extension Study of ABI-H0731 + Nucleos(t)ide as Finite Treatment for Chronic Hepatitis B Patients
    Medical condition: Chronic Hepatitis B
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-005013-76 Sponsor Protocol Number: AC15004 Start Date*: 2016-04-13
    Sponsor Name:ACCORD office [...]
    1. ACCORD office
    2. NHS Lothian R&D Office
    Full Title: GEM3: A double blind placebo controlled trial of a combination of methotrexate and gefitinib versus methotrexate alone as a treatment for ectopic pregnancy
    Medical condition: Ectopic pregnancy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10014166 Ectopic pregnancy PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA